May 19, 2021
Current guidelines strongly recommend use of the therapy for cardiology, diabetes patients
In a series of presentations at ACC.21, the virtual meeting of the American College of Cardiology, researchers delivered data to confirm two observations about cardiovascular outcomes in heart failure patients with or without type 2 diabetes (T2D) and/or chronic kidney disease (CDK). First, the use of SGLT2 inhibitors is associated with reduced risk of cardiovascular death, worsening heart failure, and/or hospitalization for heart failure, and second, SGLT2i agents are woefully underused.
In a presentation titled, “Just Go With the Flo(zin): SGLT2i Should Be Added to A Few, Some, Most, All HFrEF Patients?”, Glenn Herrington, PharmD, Ambulatory Care Cardiology Pharmacist at New Hanover Regional Medical Center in Wilmington, North Carolina, reviewed findings from EMPA-REG OUTCOME, CANVAS PROGRAM,DECLARE-TIMI 58, VERTIS CV, DAPA-HF, and EMPEROR-REDUCED to assess benefits and
AFib Rhythm Control Versus Rate Control Strategy in Heart Failure Showed No Differences
RAFT-AF study showed type of heart failure may influence treatment strategies
RAFT-AF study showed the type of heart failure may influence treatment strategies for heart rate management vs. arrhythmia control in in patients with heart heart and atrial fibrillation. Getty Images
May 19, 2021 Among patients with both heart failure and atrial fibrillation (AFib), treatment strategies focused on controlling the heart rhythm using catheter ablation and those focused on controlling the heart rate using drugs and/or a pacemaker, showed no significant differences in terms of death from any cause or progression of heart failure This was the result of RAFT-AF study presented at the American College of Cardiology (ACC) 2021 Scientific Session.
ECMO Increased Survival in Refractory Out-of-Hospital Cardiac Arrest
This hyperinvasive approach performed better than expected outcomes also seen in patients who received standard advanced cardiac life support
ECMO unit in use to support a severely ill patient at the University of Michigan. ECMO was shown to imporve survival and neuro outcomes in sudden cardiac arrest patients who do not respond to standard therapy.
May 19, 2021 A subgroup of patients who experienced an out-of-hospital cardiac arrest (OHCA) that did not respond to standard advanced cardiac life support (ACLS), were immediately transported to a cardiac care center and placed on extracorporeal membrane oxygenation (ECMO) were more likely to have survived with good brain function six months later. The outcomes in these patients were better than similar patients who received standard care.
May 19, 2021
Among patients at low risk for surgery, TAVI with the Evolut prosthetic valve (Medtronic) is noninferior to surgery with regard to the endpoint of death or disabling stroke at 2 years, according to additional data from the Evolut Low-Risk Trial.
The findings strengthen the original results, presented at American College of Cardiology (ACC) 2019 meeting and simultaneously published in the
New England Journal of Medicine, which showed noninferiority of TAVI compared with surgery for death and disabling stroke at 24 months in a Bayesian analysis once 850 of the 1,414 enrolled patients had reached 12-month follow-up.
In the complete analysis, presented by John Forrest, MD (Yale School of Medicine, New Haven, CT), yesterday at EuroPCR 2021, all patients had completed 2-year follow-up, representing 97.3% and 92.3% of the patients originally randomized to TAVI and surgery, respectively. Longer-term follow-up will evaluate patient endpoints out to 10 years, said Forrest.
email article
Extended therapeutic-level prophylactic anticoagulation with rivaroxaban (Xarelto) for COVID-19 patients with elevated D-dimer levels wasn t better and carried more bleeding risk than lower hospital-only doses, the ACTION trial showed.
Standard prophylactic-level dosing actually won on mortality, duration of hospitalization, and duration of oxygen use through 30 days more often compared with the more intensive regimen, reported Renato Lopes, MD, PhD, of the Duke Clinical Research Institute in Durham, North Carolina, at the virtual American College of Cardiology (ACC) meeting.
The trial randomized 615 patients to a standard approach of in-hospital prophylactic-dose anticoagulation or to a strategy with rivaroxaban (20 mg daily in hospital) if stable or enoxaparin (1 mg/kg twice daily) if unstable while in the hospital then rivaroxaban continued through day 30 whether still in the hospital or discharged home.